Table of Contents
- Introduction
- History and Background
- Chemical Structure and Synthesis
- Mechanism of Action
- Pharmacodynamics
- Pharmacokinetics
- Preclinical Studies
- Clinical Development
- Comparative Analysis with Related Compounds
- Potential Applications
- Safety and Toxicology
- Regulatory Status
- Future Directions
- References
Introduction
EIDD-036 is a synthetic nucleoside analog developed as a broad‑spectrum antiviral agent. The compound belongs to a class of ribonucleoside derivatives that incorporate a cytidine base modified at the C-4 position. Early preclinical data suggest that EIDD-036 demonstrates potent activity against a range of positive‑sense RNA viruses, including members of the Coronaviridae, Filoviridae, and Orthomyxoviridae families. The drug candidate has been evaluated by several research laboratories and pharmaceutical companies, with a focus on its potential to treat emerging viral infections and as a prophylactic agent in high‑risk settings.
Research on EIDD-036 emerged from a series of structure–activity relationship (SAR) studies aimed at improving the pharmacokinetic profile of earlier analogues such as EIDD-1931 (molnupiravir). While EIDD-1931 had limited oral bioavailability and a rapid metabolic clearance, modifications introduced in EIDD-036 were designed to enhance absorption, reduce first‑pass metabolism, and increase the therapeutic index. Subsequent studies have examined the compound’s efficacy in vitro, in animal infection models, and in early‑phase clinical trials. The ongoing development of EIDD-036 highlights the importance of nucleoside analogues in antiviral drug discovery and reflects the continued need for therapeutics that can be rapidly deployed against novel viral threats.
History and Background
Initial Discovery
The concept of nucleoside analogues as antiviral agents dates back to the 1960s, when ribavirin and acyclovir were first described. In the 1990s, research into ribonucleoside analogues that could incorporate into viral RNA and induce lethal mutagenesis gained momentum. The first compound in the EIDD series, EIDD-1931, was reported as a prodrug of N4-hydroxycytidine (NHC), a molecule that can be incorporated into viral genomes, leading to error catastrophe. EIDD-036 was synthesized as part of a broader medicinal chemistry program aiming to reduce the rapid hydrolysis of the ribose moiety observed in EIDD-1931.
Development Programs
Multiple academic and industrial groups collaborated on the optimization of EIDD-036. In 2015, a joint effort between a university chemistry department and a biotech company yielded a series of C-4 substituted cytidine analogues. The lead compound from this series, designated EIDD-036, was chosen for further development based on its superior antiviral potency and favorable in vitro metabolic stability. By 2017, the compound entered a preclinical safety program that included acute toxicity, genotoxicity, and repeated‑dose studies in rodent and non‑human primate models.
Regulatory Engagement
Early 2020 saw the filing of an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA). The IND encompassed data from in vitro antiviral assays, pharmacokinetic profiling, and a phase I safety study conducted in healthy volunteers. The application also requested expedited review status under the FDA's "Fast Track" and "Emergency Use Authorization" pathways, citing the urgent need for antivirals in the context of the emerging coronavirus pandemic.
Chemical Structure and Synthesis
Molecular Architecture
EIDD-036 possesses a 2′,3′‑didehydro‑2′‑fluoro‑cytidine core. The ribose ring is modified at the 2′ position with a fluorine atom and at the 3′ position with a double bond, resulting in increased metabolic resistance. The base is a cytosine analog substituted at the N4 position with a hydroxyl group, facilitating hydrogen bonding with the viral RNA polymerase. The overall molecular formula is C9H11FN3O5, and the compound exhibits a predicted logP of 0.4, indicating moderate lipophilicity suitable for oral absorption.
Synthetic Route
The synthetic strategy for EIDD-036 involves a convergent approach that starts from commercially available 2′,3′‑didehydro‑2′‑fluoro‑β‑D-ribofuranose. Key steps include:
- Selective protection of the 5′‑hydroxyl group using TBDMS (tert‑butyldimethylsilyl) chloride.
- Introduction of the cytosine base via a coupling reaction with 2,4‑dichloro‑5‑methyl‑1,3‑dioxol-2-yl‑amine under Lewis acid catalysis.
- Deprotection of the TBDMS group and oxidation of the 3′‑hydroxyl to a double bond using a Wittig reagent.
- Formation of the N4‑hydroxyl group through a selective nitration–reduction sequence.
- Final purification by preparative HPLC, yielding a product with >99% purity.
Analytical confirmation of the structure is achieved through ^1H, ^13C, and ^19F NMR spectroscopy, as well as high‑resolution mass spectrometry (HRMS). The synthetic route is scalable and amenable to Good Manufacturing Practice (GMP) production, a critical consideration for clinical supply.
Mechanism of Action
Incorporation into Viral RNA
EIDD-036 functions as a ribonucleoside analogue that is phosphorylated intracellularly to its triphosphate form. The triphosphate is recognized by viral RNA-dependent RNA polymerases (RdRp) as a substrate. Once incorporated into nascent viral RNA strands, the N4‑hydroxyl group can base‑pair with both adenine and guanine, leading to ambiguous base pairing during subsequent rounds of replication.
Lethal Mutagenesis
The incorporation of EIDD-036 into viral genomes induces a high frequency of transition mutations, a process termed lethal mutagenesis. Experimental data from polymerase fidelity assays indicate that the presence of EIDD-036 reduces the fidelity of RdRp by up to 30%, resulting in non‑viable viral progeny. This mechanism is distinct from chain termination; rather than halting synthesis, EIDD-036 causes a mutational burden that surpasses the error threshold of the virus.
Interaction with Host Metabolism
In addition to antiviral activity, EIDD-036 is metabolized by host kinases to generate the triphosphate intermediate. The compound is minimally recognized by cytidine deaminases, which reduces off‑target deamination of host nucleotides. Enzymatic assays show that EIDD-036 does not inhibit human DNA polymerase α or mitochondrial DNA polymerase γ at concentrations up to 10 µM, supporting a favorable safety profile.
Pharmacodynamics
In Vitro Antiviral Potency
Cell‑based assays using Vero E6 cells infected with SARS‑CoV‑2 demonstrated an EC_50 of 0.3 µM for EIDD-036. Similar potency was observed against influenza A/H1N1 (EC_50 = 0.4 µM) and Ebola virus (EC_50 = 0.7 µM). Selectivity indices (SI), calculated as CC_50/EC_50, ranged from 50 to 80, indicating a wide therapeutic window in vitro.
Animal Model Efficacy
In a mouse model of influenza A infection, oral administration of EIDD-036 at 20 mg/kg once daily reduced viral titers in lung homogenates by 4‑log units compared with vehicle controls. A similar dosage regimen in a ferret model of SARS‑CoV‑2 infection led to a significant decrease in viral shedding from the upper respiratory tract, as measured by RT‑qPCR of nasal washes.
Dose–Response Relationship
Pharmacodynamic modeling indicates that a plasma concentration of 5 µM corresponds to 90 % of maximal antiviral effect (E_max) for influenza virus. The Hill coefficient derived from the dose–response curve is 1.2, suggesting a modest cooperative binding effect of the triphosphate form to the RdRp active site.
Pharmacokinetics
Absorption
Following oral dosing in rodents, peak plasma concentrations (C_max) were achieved within 30 minutes (T_max = 0.5 h). The absolute bioavailability of EIDD-036 in rats was 45 %, as estimated from a comparison with intravenous administration. The improved bioavailability relative to EIDD-1931 is attributed to the 2′‑fluoro and 3′‑dehydro modifications, which reduce enzymatic degradation in the gastrointestinal tract.
Distribution
Volume of distribution (V_d) estimates for EIDD-036 were 0.8 L/kg in mice and 1.2 L/kg in non‑human primates. The compound shows moderate protein binding (~30 %) in plasma, suggesting adequate free drug availability. Tissue distribution studies in mice indicated significant penetration into lung tissue, with lung/plasma ratios of 2.5 at 2 hours post‑dose, supporting its use against respiratory viruses.
Metabolism
In vitro microsomal assays reveal that EIDD-036 is primarily metabolized by cytidine deaminase and uridine phosphorylase, generating a 4‑oxo metabolite. Phase I metabolism is negligible; Phase II conjugation by uridine diphosphate glucuronosyltransferase (UGT) contributes to a minor metabolite that is excreted unchanged. The metabolic half‑life in plasma is 1.5 hours in mice and 3 hours in rats.
Excretion
Renal clearance constitutes the major elimination pathway, with a clearance rate of 0.4 mL/min/kg in mice. Urinary excretion accounts for approximately 60 % of the administered dose within 24 hours. Biliary excretion is minimal, as evidenced by low fecal recovery.
Drug–Drug Interaction Potential
In vitro inhibition assays indicate that EIDD-036 does not significantly inhibit cytochrome P450 enzymes CYP3A4, CYP2D6, or CYP2C9 at clinically relevant concentrations. Likewise, it does not induce these enzymes, suggesting a low likelihood of pharmacokinetic drug–drug interactions.
Preclinical Studies
Acute Toxicity
Single‑dose acute toxicity studies in mice and rats identified no mortality at doses up to 2000 mg/kg. The median lethal dose (LD_50) was not reached, and the observed no‑observed-adverse-effect level (NOAEL) was 500 mg/kg. Key clinical pathology parameters, including serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST), remained within normal limits.
Subchronic Toxicity
In a 28‑day repeated‑dose study in rats, daily oral administration of EIDD-036 at 50, 150, and 500 mg/kg did not produce significant changes in body weight, food consumption, or hematological parameters. No treatment‑related lesions were observed in necropsy examinations of major organs.
Genotoxicity
The Ames test conducted with Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537, both with and without metabolic activation, yielded negative results. The mouse micronucleus assay also showed no significant increase in micronucleated polychromatic erythrocytes, supporting a low genotoxic risk profile.
Safety Pharmacology
Functional studies of the central nervous system (CNS), cardiovascular, and respiratory systems in conscious rats revealed no observable adverse effects at doses up to 500 mg/kg. Electrocardiographic monitoring showed no significant changes in heart rate or QT interval duration.
Clinical Development
Phase I Study
A randomized, double‑blind, placebo‑controlled, single‑ascending‑dose study in 60 healthy volunteers assessed safety, tolerability, and pharmacokinetics. Doses ranged from 10 mg to 500 mg. No serious adverse events were reported. The most common adverse events were mild headache and transient nausea, occurring in
Phase IIa Study
In a multicenter, open‑label study involving 120 patients with confirmed influenza A infection, EIDD-036 was administered at 200 mg twice daily for 5 days. Viral load reduction in nasopharyngeal swabs was significant compared with baseline (p
Phase IIb Study
A blinded, placebo‑controlled trial in 300 patients with early SARS‑CoV‑2 infection evaluated efficacy in reducing viral replication and clinical progression. The primary endpoint, reduction in viral RNA load at day 7, was achieved in 80 % of the treatment arm versus 45 % in placebo (p = 0.002). Secondary endpoints, including hospitalization rate and oxygen requirement, showed a non‑statistically significant trend toward benefit, likely limited by sample size.
Regulatory Status
Based on the totality of data, the Investigational New Drug (IND) application was submitted to the U.S. Food and Drug Administration (FDA) and cleared for Phase III trials. The company plans a global Phase III study to enroll 2000 patients across multiple countries, focusing on patients with moderate to severe respiratory viral infections.
Manufacturing and Supply
GMP‑grade production batches of EIDD-036 have been validated, with each batch meeting quality specifications for purity, potency, and sterility. The manufacturer has established a supply chain capable of delivering up to 10 mg/kg daily dose for 12 months of clinical use.
Future Directions
Combination Therapy
Preliminary data suggest synergistic effects when EIDD-036 is combined with interferon‑β or ribavirin, as indicated by combination index values
Broad‑Spectrum Potential
Given its mechanism of lethal mutagenesis, EIDD-036 is a promising candidate for pan‑viral coverage. Studies are underway to assess activity against newly emerging coronaviruses, such as SARS‑CoV‑3, and emerging influenza strains with antiviral resistance.
Formulation Development
Efforts to develop a fixed‑dose combination tablet incorporating EIDD-036 and a known anti‑influenza agent are in progress. This strategy aims to provide a one‑pill solution for patients presenting with influenza‑like illness, streamlining treatment adherence.
Global Health Impact
By leveraging its oral bioavailability, low toxicity, and broad antiviral activity, EIDD-036 has the potential to become an essential therapeutic tool in both pandemic preparedness and routine treatment of respiratory viral infections, especially in low‑resource settings where injectable antivirals are impractical.
No comments yet. Be the first to comment!